TriApex Laboratories
No. 9 Xinglong Road, Jiangbei New Area, Nanjing, Jiangsu, 211800, China
Overview
TriApex is an innovative CRO dedicated to providing disease-oriented one-stop solutions to enable R&D for global pharmaceutical enterprises and research institutions.
- Total investments
- 1
- Lead investments
- 1
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Biopharma
- Pharmaceutical
Investment portfolio
- Xellar Biosystems
Led · Equity · Jul 2024
Xellar Biosystems develops a closed-loop platform that integrates human organ-on-chip models, automated experimentation, high-content imaging, multi-omics analysis, and machine learning to generate high-quality, human-relevant biological data. The company aims to produce multi-dimensional datasets under physiologically relevant conditions to enable biological foundation models and virtual cell systems for prediction of mechanism of action, toxicity, disease progression, and therapeutic response. Xellar positions its approach as an alternative to traditional preclinical models that rely on animals or simplified in vitro assays. With the $50 million Series A/A+ financing, Xellar plans to scale automated biological data generation, expand computational and AI teams, and accelerate virtual cell technology development. The company presents this platform as a way to make drug discovery faster, more predictive, and more scalable. Xellar was founded in 2022.
Team
No current team members are available.